For example, HER2 amplification is a driver in 12–20% of breast cancers, correlates with poor survival, and has been effectively targeted to improve outcomes in patients with HER2 amplified breast cancer [6–9]. This evidence concerns the gene ERBB2 and breast carcinoma.